Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study

NCT ID: NCT00670371

Last Updated: 2009-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective is to find determinants for the subjective and objective burden of informal caregivers to patients who are requiring continued antipsychotic treatment for functional psychoses among factors related to the patient, the health care and support provision system and the informal caregiver him/her-self.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study also comprises a descriptive part with the aim:

* To describe clinical characteristics, symptoms, and functioning in the patient group.
* To describe patient resource use in terms of support from the health care and social care sector.
* To describe the socio-economic situation, the general and psychological health, and the coping ability of the informal caregivers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Functional Psychoses Informal Caregivers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Caregiver burden

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.

No interventions assigned to this group

2

Closest relative(s) /informal caregiver(s)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of informed consent
* Patients, male or female, aged 18 years or more, suffering or having suffered from a psychotic episode and being in need of continuous antipsychotic medication.
* The respective patient must have at least one informal caregiver.
* Subjects (patients and informal caregivers) must be able to read and write.

Exclusion Criteria

* Diagnosis of dementia and such cognitive impairment which makes self assessments even with assistance unreliable (patients and informal caregivers).
* Involvement in the planning and conduct of the study (patients and informal caregivers).
* Other concurrent medical condition interfering with ability to complete study (patients and informal caregivers).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eva Dencker Vansvik

Role: STUDY_DIRECTOR

AstraZeneca, MC, Sweden

Lena Flyckt

Role: PRINCIPAL_INVESTIGATOR

Danderyds Hospital, Stockholm

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research site

Bromma, , Sweden

Site Status

Research Site

Danderyd, , Sweden

Site Status

Research Site

Falköping, , Sweden

Site Status

Research Site

Huddinge, , Sweden

Site Status

Research Site

Lidingö, , Sweden

Site Status

Research Site

Ljungby, , Sweden

Site Status

Research Site

Malmo, , Sweden

Site Status

Research Site

Solna, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NSE-DUM-2007/1

Identifier Type: -

Identifier Source: org_study_id